Welcome to our dedicated page for Aethlon Medical news (Ticker: AEMD), a resource for investors and traders seeking the latest updates and insights on Aethlon Medical stock.
Aethlon Medical, Inc. (Nasdaq: AEMD) is a clinical-stage medical device company headquartered in San Diego, California, with news flow centered on development of its investigational Hemopurifier device. Company announcements highlight progress in oncology and infectious disease programs, capital markets activity, and regulatory interactions that shape the outlook for AEMD stock.
Recent news releases describe Aethlon’s ongoing safety, feasibility, and dose-finding oncology trial in Australia, where the Hemopurifier is being evaluated in patients with solid tumors who have not responded to anti-PD-1 therapies. Updates have covered early observations on extracellular vesicles, microRNAs, and lymphocyte counts in initial cohorts, along with protocol amendments and site activity. The company also reports collaborations in Long COVID research, including preclinical data showing that its GNA affinity resin binds extracellular vesicles in Long COVID plasma and depletes EV-associated microRNAs linked to inflammatory pathways.
Investors following AEMD news will also see regular disclosures on financing transactions, such as public offerings and private placements of common stock, pre-funded warrants, and common stock purchase warrants. These items detail gross proceeds, warrant terms, and intended uses of capital for clinical trials, research and development, and working capital. Additional coverage includes patent issuances related to Long COVID and COVID-19-associated coagulopathy, Nasdaq listing compliance updates, and scheduling of quarterly financial results and conference calls.
This news page aggregates Aethlon Medical’s press releases and related coverage so readers can review clinical updates, scientific publications, financing events, and regulatory milestones in one place. For those tracking AEMD, it offers a structured view of how the company communicates progress on the Hemopurifier and its broader development strategy over time.
Aethlon Medical (Nasdaq: AEMD) announced FDA approval for a supplement to its Investigational Device Exemption (IDE) enabling the Hemopurifier® to be tested in COVID-19 patients. The feasibility study will include up to 40 subjects in ICUs with acute lung injury and severe symptoms. The Hemopurifier, previously tested for hepatitis C and Ebola, is designated as a Breakthrough Device for life-threatening viral infections and advanced cancer. CEO Timothy C. Rodell believes the device could improve outcomes for severely affected COVID-19 patients.
Aethlon Medical, Inc. (Nasdaq: AEMD) announced it will release its financial results for Q4 FY2020 on June 25, 2020, at 4:15 PM Eastern Time. A conference call is scheduled for the same day at 4:30 PM Eastern, where management will review results and corporate developments, followed by a Q&A session. The Hemopurifier®, Aethlon's immunotherapeutic device, has received FDA's Breakthrough Device designations for cancer and viral infections, aiming to address critical unmet needs in global health.